Search

Your search keyword '"Huy N. Trinh"' showing total 214 results

Search Constraints

Start Over You searched for: Author "Huy N. Trinh" Remove constraint Author: "Huy N. Trinh"
214 results on '"Huy N. Trinh"'

Search Results

151. Similar Viral Suppression Rates with Adefovir (ADV) Based Combination Therapy with Either Entecavir (ETV) or Telbivudine (LdT)/Lamivudine (LAM) in Chronic Hepatitis B Patients with Prior Antiviral Resistance or Partial Drug Response at 6 and 12 Months

152. Long-Term Treatment Outcome of Entecavir (ETV) Monotherapy in Treatment-Naive Hepatitis B e Antigen-positive Chronic Hepatitis B (CHB) Patients in a Real-Life Setting

153. How Many Patients with Chronic Hepatitis B (CHB) Seen at a U.S. Gastroenterology Clinic Would Be Eligible for Antiviral Therapy?

154. Long-Term Outcome of Chronic Hepatitis B Patients Initially Treated with Adefovir Dipivoxil in a Community Practice

157. Sa1005 Antiviral Treatment Eligibility and Treatment Rates in Patients With Chronic Hepatitis B (CHB) At Primary Care, Community and University Referral Clinics: A Comparative Study

158. Su1286 Differences Between Community and Academic Cohorts of Patients With Chronic Hepatitis B (CHB) in the Development of Hepatocellular Carcinoma (HCC)

161. Maintenance of Complete Viral Suppression (CVS) with Tenofovir (TDF) Monotherapy Following CVS with Entecavir (ETV)+TDF Combination in Patients with Prior ETV Partial Response

162. Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study

164. Mo1893 Evaluation of Treatment-Eligibility for Antiviral Therapy During Follow-up in Chronic Hepatitis B Patients Initially Ineligible for Treatment

165. Mo1896 Chronic Hepatitis B (CHB) Treatment Eligibility and Actual Treatment Rates at Community Gastroenterology Clinics and Primary Care Clinics

168. Mo1904 Treatment Evaluation of Chronic Hepatitis B (CHB) Patients at Tertiary Care and Community Centers

169. Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints

170. 467 Maintenance of Complete Viral Suppression (CVS) With Tenofovir (TDF) Monotherapy in Patients With Prior Partial Response to Entecavir (ETV) Who Have Achieved CVS With ETV+TDF Combination Therapy

171. Su2044 Incidence of Hepatocellular Carcinoma (HCC) in Non-Cirrhotic and Cirrhotic Patients With Chronic Hepatitis B (CHB): Results of a Multicenter Cohort Study

172. Adefovir (ADV) Partial Response in Patients with Chronic Hepatitis B (CHB): Switch Versus Add-On Therapy

173. Risk Factors for Hepatitis C Virus (HCV) Infection in Asian American Patients: A Case-Control Study

175. Proportion of Patients Who Were Previously Ineligible for Anti-HBV Therapy Who Became Eligible After 12 Months of Follow-up: Application of U.S. Panel and AASLD Guidelines

177. Tenofovir Disoproxil Fumarate (TDF) Shows Similar Virologic Suppression and Safety Between Asians and Non-Asians With Chronic Hepatitis B (CHB)

178. Rapid Complete Viral Suppression (CVS) With Entecavir (ETV) in Adefovir (ADV)-Experienced Patients: Interim Report for a Multicenter Study

179. Incidence of Hepatitis B E Antigen (HBeAg) Seroconversion and Suboptimal Response in Chronic Hepatitis B (CHB) Patients Treated With Entecavir 0.5 mg Daily in Routine Clinical Practice

180. Annual Incidence for Hepatocellular Carcinoma (HCC) in Non-Cirrhotic Patients With Chronic Hepatitis B (CHB) and Cirrhotic Patients of All Etiologies

181. Hepatitis B Virus (HBV) Reverse Transcriptase Mutation Prevalence Was Low in Treatment-NaïVE Patients With Chronic Hepatitis B (CHB) Using Inno-Lipa HBV DR3 in a Prospective Multicenter Study

182. High Rate of Recurrent Hepatitis B Viremia Following Treatment-Induced Hepatitis B E Antigen (HBeAg) Seroconversion

183. Long-Term Treatment Response to Entecavir and Adefovir in Treatment-NaïVE Chronic Hepatitis B E Antigen-Negative Patients in a Community Setting

185. 314 Randomized Controlled Trial of Pegylated Interferon-Alpha 2a and Ribavirin in Patients With Treatment-NaïVE Chronic Hepatitis C Genotype 6

186. W1011 Prevalence, Risk Factors, and Disease Knowledge of Chronic Hepatitis B (CHB) Infection in Vietnamese Americans in California: A Prospective Study

187. 80 Hepatocellular Carcinoma Incidence in a Cohort of 981 U.S. Patients With Chronic Hepatitis B Without Cirrhosis and Patients With Cirrhosis of All Etiologies

188. M1892 Hepatitis B-E Antigen Positive (HBeAg+) Chronic Hepatitis B (CHB) Patients With Precore (PC) and Basic Core Promoter (BCP) Mutations

189. 636 High Rate of Complete Viral Suppression With Combination Therapy With Tenofovir Using Entecavir or Lamivudine/Emtricitabine in Patients With Chronic Hepatitis B and Prior Monotherapy Failure

190. M1893 Hepatitis B Virus Reverse Transcriptase Mutations Were Not Detected in Treatment-NaïVE Patients With Chronic Hepatitis B Using Inno Lipa HBV DR3: A Prospective Multicenter Study

191. M1903 Long-Term Outcome of Treatment-NaïVE Chronic Hepatitis B (CHB) E Antigen-Negative Treated With Entecavir 0.5 Mg (ETV) or Adefovir 10 Mg (ADV) in a Real-Life Community Setting

192. T1967 Asian Ethnicity is a Significant Predictor for Viral Dominance by HBV in HBV/HCV Co-Infected Patients: A Multicenter, Matched Case-Control Study

193. 634 Treatment Efficacy of Entecavir (ETV) Therapy in Patients Previously Treated With Adefovir (ADV): Interim Report for a Multicenter Study

194. Prevalence, Risk Factors, and Disease Knowledge of Chronic Hepatitis B (CHB) Infection in Vietnamese Americans in the San Francisco Bay Area, California: A Cross-Sectional Study

195. W1809 Changes in Creatinine Clearance (CrCl) in Chronic Hepatitis B (CHB) Patients Treated with Adefovir Dipivoxil (ADV): A Case-Control Study

196. 322 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil

197. W1807 Long-Term Outcome of Chronic Hepatitis B Patients Initially Treated with Entecavir in a Real-Life Clinical Setting

198. M1777 Poor Adherence to Screening for Hepatocellular Carcinoma (HCC), Especially in Patients with Chronic Hepatitis B (CHB) Without Cirrhosis Compared to Patients with Cirrhosis of All Etiologies

199. 11 Treatment Response and Tolerability to Pegylated Interferon (PEG Inf) and Ribavirin (RBV) in Treatment-Naïve Asian American Patients with Chronic Hepatitis C and Genotype 1, 2/3 and 6

200. 319 Response to Entecavir (ETV) in Patients with Chronic Hepatitis B (CHB) and Prior Suboptimal Response to Adefovir (ADV): Interim Report of a Multicenter Study

Catalog

Books, media, physical & digital resources